Wet AMD sufferers unaware of pre-existing AMD

Article

Current screening of patients with age-related macular degeneration (AMD) does not sufficiently identify those patients most at risk of wet AMD and hence is unable to prevent its development, according to a report published in the June 2008 issue of Eye.

Current screening of patients with age-related macular degeneration (AMD) does not sufficiently identify those patients most at risk of wet AMD and hence is unable to prevent its development, according to a report published in the June 2008 issue of Eye.

Itay Chowers, MD of the Hadassah-Hebrew University Medical Center, Israel and colleagues conducted a retrospective analysis of NVAMD subjects (n=268) and compared characteristics between those subjects who were aware of their AMD before the NVAMD diagnosis (n=83), and those who were not (n=185).

The researchers found that there were no significant differences between the two groups in terms of demographic characteristics, visual acuity, lesion size and lesion composition. Patients who were not previously aware of their AMD were more likely to have a history of smoking (41%) than those who were aware (26%); patients with a positive family history of AMD were more likely to be aware of their own AMD before the NVAMD diagnosis (20%) than those who did not (10%).

The team concluded that the majority of patients receiving an NVAMD diagnosis were previously unaware that they had AMD, although early AMD detection may not entail detection of treatable choroidal neovascularization lesions.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.